EGFR and non-small cell lung carcinoma: Previous studies have confirmed a lack of response to ICIs in metastatic NSCLC patients with EGFR mutations, and one of the potential mechanisms could be the low expression of PD-L1 or absence of infiltrating T cells in the TME (6, 7, 15).